An observational study in Juxtarenal Aortic Aneurysm and Pararenal Aneurysm, sponsored by Clinical Centre of Serbia. Completed at 1 site in Serbia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-07-22.
Sponsored by Clinical Centre of Serbia · Observational
Background: Open repair remains the gold standard for fit patients with complex AAA. In the past decade, an evolution of devices, design, components, and delivery systems expanded the application of EVAR in these challenging anatomies. Fenestrated stent-grafts are now commercially available for the repair of complex AAA in the United States and Europe. Initial reports have demonstrated a high technical success rate, low renal dysfunction rate, and low morbidity and mortality, with promising short- and long-term results. Other reports have shown excessive morbidity and mortality with fenestrated EVAR (FEVAR). Studies comparing endovascular and open repair are sparse, especially when it concerns long-term outcomes. There are till nowadays only two propensity score-matched studies, one showing worse short-term and another long-term clinical outcome for fenestrated-branched EVAR (F/BEVAR) over open surgical repair (OSR).
Aim: The aim of this study will be to compare F/BEVAR versus open AAA repair on short- and long-term clinical outcomes for the treatment of juxta- and pararenal AAA.
Methodology: This is a prospective cohort study from the four high-volume AAA repair centers: Belgrade/Serbia, Bologna/Italy, Milan/Italy, Dijklander/Netherland, Amsterdam/Netherland, and Helsinki/Finland. Data will be collected on demographics, baseline comorbidities, AAA parameters (diameter and localization), laboratory values, intra-, and postoperative data. Follow-up examinations (clinical visits and color duplex ultrasonography, CT scans) will be performed 1, 6, and 12 months after the intervention, and annually thereafter. Propensity score analysis will be performed by matching open repair patients to endovascularly treated controlling for demographics and baseline comorbidities.
Endpoints: Primary endpoints are all-cause mortality and the freedom from aortic-related reintervention. The secondary endpoint is the 30-day complication rate, especially acute kidney injury according to the RIFLE criteria.
Background Endovascular abdominal aortic aneurysm repair (EVAR) has gained widespread acceptance in the treatment of patients with abdominal aortic aneurysms (AAA). Prospective randomized trials (RCTs) have demonstrated several short-term advantages over open repair such as less blood loss, operative time, hospital stay, morbidity, and mortality. The applicability of EVAR is limited by the presence of inadequate neck or involvement of the visceral arteries. Thus consequently open AAA repair is now being performed primarily for complex aortic anatomies, such as juxtarenal and pararenal aneurysms. Open repair remains the gold standard for fit patients with complex AAA. In the past decade, an evolution of devices, design, components and delivery systems expanded the application of EVAR in these challenging anatomies. Fenestrated stent-grafts are now commercially available for the repair of complex AAA in the United States and Europe. Initial reports have demonstrated a high technical success rate, low renal dysfunction rate and low morbidity and mortality with promising short- and long-term results. Other reports have shown excessive morbidity and mortality with fenestrated EVAR (FEVAR). Studies comparing endovascular and open repair are sparse, especially when it concerns long-term outcomes. There are till nowadays only two propensity score-matched studies, one showing worse short-term and another long-term clinical outcome for fenestrated-branched EVAR (F/BEVAR) over open surgical repair (OSR). Vascular surgeons are therefore left with a paucity of data to guide decision-making.
Study objectives:
Inclusion criteria:
Exclusion criteria:
Sample size To ensure sufficient statistical power to answer hypothetical questions, approximately 700 subjects will be entered into the database. Aortic-related reintervention rate is the primary endpoint being used to calculate the sample size. Assuming a difference of 7% in the late reintervention rate between endovascular and open repair, 221 patients would be required in each arm to achieve a statistical power of 85% at p=0.05. With two arms (endovascular versus open), assuming a 20% rate of missing data, a total N of 550 patients is required.
Research Design
This is a prospective study including patients treated for juxta- and pararenal AAA from 2011 through 2021 treated at six different vascular surgery centers:
Procedures Involved The study does not involve any patient contact and will not impact the care that patients receive. Data regarding the patients will be compiled and analyzed to accomplish the proposed study objectives. Data collection will include demographic information, patient-related factors, and comorbidities, diagnostic imaging information, laboratory data, surgical procedure information, complications of the surgery, and outcomes.
Multi-Institutional research After the data has been collected at a participating institution, the data will be transmitted to a central analytic center located at the Clinic for Vascular and Endovascular Surgery/Clinical Center of Serbia/Medical Faculty, University of Belgrade.
Risks to Subjects As this is a prospective observational study, there is no potential for physical risks to subjects. There is a minimal risk of breach of confidentiality that could occur when patient information is collected and analyzed for the proposed study. However, appropriate measures will be taken to minimize the risk as much as possible. All information recorded will be de-identified. This study will abide by all regulations related to protecting human subjects and protected health information.
Potential Benefits to Subjects There is no direct benefit to the subjects. However, future patients with juxta- and pararenal AAA may benefit from improved care as a result of this study.
Statistics and Data Analysis Continuous variables will be described using the median and interquartile range or mean and standard deviation. Categorical variables will be described using frequencies and percentages. Group comparisons will be performed by using the Student t-test or Mann-Whitney U test, as appropriate. Categorical data will be expressed as percentages and were compared using the chi-square test or Fisher exact test. Propensity score analysis will be performed by matching endovascular to open surgery group in a 1:1 ratio controlling for demographics, baseline comorbidities, and AAA parameters. Differences will be considered statistically significant at p \< 0.05. The cumulative incidences of all-cause mortality and aortic-related complications will be estimated using the Kaplan-Meier method. Differences between curves will be tested using the log-rank test. Analyses will be done with SPSS software, version 20.0 (SPSS, Chicago, IL, USA).
Conflict of Interest The investigators have no conflict of interest to report.
Funding Source There are no plans to apply for grants or additional funding. No funding is required for the completion of this study.
Publication Plan All research personnel listed on this protocol will be eligible for authorship in any resulting abstracts and publications in accordance with the qualifications outlined by the International Committee of Medical Journal Editors. The order of authors will be determined prior to manuscript development and depend on each individual's contribution to the study.
222 studies on the registry are indexed under Aortic Aneurysm; 63 are open to participants now.
This study's enrollment of 925 is above the median of 150 across 117 observational studies indexed under Aortic Aneurysm.
Browse Aortic Aneurysm studies →Clinical Centre of Serbia is the lead sponsor of 24 studies on the registry; 4 are open to participants now.
Counted across the registry records on this site, refreshed daily.
All patients with juxta/pararenal abdominal aortic aneurysm (AAA) undergoing either open surgery or complex endovascular repair.
The definition of the juxtarenal AAA will include those with a short neck (less than 1cm).
The definition of the pararenal AAA will include those where renal arteries originate from the aneurysm itself.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients undergoing open surgery due to juxta/pararenal abdominal aortic aneurysm
Procedure: Open surgery and complex EVAR due to AAA
Patients undergoing some form of endovascular abdominal aortic aneurysm repair: fenestrated, chimney, etc.
Procedure: Open surgery and complex EVAR due to AAA
There will be two cohorts: 1. Patient undergoing open surgery 2. Patients undergoing complex endovascular repair (fenestrated, chimney, etc.)
Aortic Related Reintervention.
In open surgery this will include patients who were reoperated due to: graft infection, graft thrombosis, pseudoaneurysm formation, secondary AAA rupture. In endovascular group reintervention will include different reasons: endoleak, migration, thrombosis, infection, fracture, secondary AAA rupture.
Time frame: through study completion, an average of 7 year
All-cause Mortality
Any cause of mortality duing follow-up period
Time frame: through study completion, an average of 7 year
30-day Acute Kidney Injury
Acute kidney injury was defined using RIFFLE criteria.
Time frame: 30-day acute kidney injury
| Milestone | Open Surgery Group | Endovascular Group |
|---|---|---|
| Started | 668 | 257 |
| Completed | 600 | 234 |
| Not completed | 68 | 23 |
In open surgery this will include patients who were reoperated due to: graft infection, graft thrombosis, pseudoaneurysm formation, secondary AAA rupture. In endovascular group reintervention will include different reasons: endoleak, migration, thrombosis, infection, fracture, secondary AAA rupture.
| Participants | Open Surgery Group | Endovascular Group |
|---|---|---|
| Aortic Related Reintervention. | 44 | 63 |
Any cause of mortality duing follow-up period
| Participants | Open Surgery Group | Endovascular Group |
|---|---|---|
| All-cause Mortality | 256 | 91 |
Acute kidney injury was defined using RIFFLE criteria.
| Participants | Open Surgery Group | Endovascular Group |
|---|---|---|
| 30-day Acute Kidney Injury | 182 | 39 |
Collected over 84 monhts. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Open Surgery Group | 256/600 (42.7%) | 133/600 (22.2%) | 0/600 (0%) |
| Endovascular Group | 91/234 (38.9%) | 51/234 (21.8%) | 0/234 (0%) |
| Event | Open Surgery Group | Endovascular Group |
|---|---|---|
| Srugical bleedingGeneral disorders | 38/600 | 12/234 |
| Spinal cord ischemiaNervous system disorders | 3/600 | 8/234 |
| Acute lower limb ischemiaVascular disorders | 18/600 | 8/234 |
| Acute coronary syndromeCardiac disorders | 16/600 | 3/234 |
| Wound infectionInfections and infestations | 11/600 | 6/234 |
| Prolonged intubationRespiratory, thoracic and mediastinal disorders | 14/600 | 5/234 |
| Deep vein thrombosisVascular disorders | 11/600 | 2/234 |
| Colonic ischaemiaGastrointestinal disorders | 9/600 | 3/234 |
| Stroke or transitory ischemic attackNervous system disorders | 8/600 | 2/234 |
| Wound dehiscenceSkin and subcutaneous tissue disorders | 5/600 | 2/234 |
| Age, Continuous(years) | Open Surgery Group | Endovascular Group | Total |
|---|---|---|---|
| Mean | 69.5 ± 7.1 | 73 ± 6.6 | 71.9 ± 6.9 |
| Sex: Female, Male(Participants) | Open Surgery Group | Endovascular Group | Total |
|---|---|---|---|
| Female | 150 | 25 | 175 |
| Male | 450 | 209 | 659 |
| Race and Ethnicity Not Collected(Participants) | Open Surgery Group | Endovascular Group | Total |
|---|---|---|---|
| Count of participants | — | — | 0 |
| Body mass index(kg/m2) | Open Surgery Group | Endovascular Group | Total |
|---|---|---|---|
| Mean | 26.9 ± 3.4 | 26.7 ± 3.7 | 26.7 ± 3.6 |
| Current smoker(Participants) | Open Surgery Group | Endovascular Group | Total |
|---|---|---|---|
| Count of participants | 170 | 89 | 259 |
| Hypertension(Participants) | Open Surgery Group | Endovascular Group | Total |
|---|---|---|---|
| Count of participants | 480 | 210 | 690 |
| Hyperlipidemia(Participants) | Open Surgery Group | Endovascular Group | Total |
|---|---|---|---|
| Count of participants | 413 | 144 | 557 |
| Diabetes mellitus(Participants) | Open Surgery Group | Endovascular Group | Total |
|---|---|---|---|
| Count of participants | 142 | 45 | 187 |
9 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — This will be not available freely online, but on the request.
Ran from Jan 2011 to primary completion in Jan 2022, 132 months.
Results were first posted in Jul 2024, 2 years 6 months after primary completion.
Of 44 observational studies under Aortic Aneurysm, half reached primary completion within 67 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 107. This study's 132 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Clinical Centre of Serbia